Genetically informed lung cancer medicine

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 231-241

  Pao, William ^a   Iafrate, A John ^b   Su, Zengliu ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

gene fusion; gene mutation; gene rearrangement; genetic analysis; lung cancer; protein kinase; sequencing; signal transduction pathway; targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; CETUXIMAB; CHIR 265; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; GSK 2118436; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MATUZUMAB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PANITUMUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLX 4032; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 281; XL 880; ZALUTUMUMAB;

CANCER GROWTH; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; DOWNSTREAM PROCESSING; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MELANOMA; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION;

EID: 78650034175     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2788     Document Type: Review

References (107)

1. Lee W, Jiang Z, Liu J, et al., The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-477.
2. Pleasance ED, Stephens PJ, O'Meara S, et al., A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463: 184-190.
3. Weinstein IB,. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-64.
4. Sawyers CL, Hochhaus A, Feldman E, et al., Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539. (Pubitemid 34534519)
5. Jemal A, Siegel R, Xu J, et al., Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
6. Manning G, Whyte DB, Martinez R, et al., The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
7. Ladanyi M, Pao W,. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008; 21 (suppl 2): S16-22.
8. Yun CH, Boggon TJ, Li Y, et al., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007; 11: 217-227.
9. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
10. Mitsudomi T, Morita S, Yatabe Y, et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
11. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
12. Wu JY, Wu SG, Yang CH, et al., Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14: 4877-4882.
13. Costa DB, Nguyen KS, Cho BC, et al., Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14: 7060-7067.
14. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
15. Bean J, Riely GJ, Balak M, et al., Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14: 7519-7525.
16. Zhou W, Ercan D, Chen L, et al., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070-1074.
17. Janne PA, Gray N, Settleman J,. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009; 8: 709-723.
18. Khambata-Ford S, Harbison CT, Hart LL, et al., Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 918-927.
19. Klapper LN, Glathe S, Vaisman N, et al., The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 1999; 96: 4995-5000.
20. Graus-Porta D, Beerli RR, Daly JM, et al., ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
21. Muthuswamy MS,. A method of beam-couch intersection detection. Med Phys 1999; 26: 229-235.
22. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
23. Heinmoller P, Gross C, Beyser K, et al., HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003; 9: 5238-5243.
24. De Greve J, Teugels E, De Mey J, et al., Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. J Thorac Oncol 2009; 4:(abstr): S307.
25. Morris SW, Kirstein MN, Valentine MB, et al., Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
26. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
27. Takeuchi K, Choi YL, Soda M, et al., Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008; 14: 6618-6624.
28. Choi YL, Takeuchi K, Soda M, et al., Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008; 68: 4971-4976.
29. Wong DW, Leung EL, So KK, et al., The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115: 1723-1733.
30. Takeuchi K, Choi YL, Togashi Y, et al., KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009; 15: 3143-3149.
31. Bang Y, Kwak EL, Shaw AT, et al., Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Thorac Oncol 2010; 28:(abstr 3): 7s.
32. Shaw AT, Yeap BY, Mino-Kenudson M, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
33. Rodrigues GA, Park M,. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994; 9: 2019-2027.
34. Hammond DE, Urbe S, Vande Woude GF, et al., Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001; 20: 2761-2770.
35. Bean J, Brennan C, Shih JY, et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
37. Schmidt L, Junker K, Nakaigawa N, et al., Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343-2350.
38. Ding L, Getz G, Wheeler DA, et al., Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
39. Ma PC, Kijima T, Maulik G, et al., c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-6281.
40. Tyner JW, Fletcher LB, Wang EQ, et al., MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010; 70: 6233-6237.
41. Eder JP, Shapiro GI, Appleman LJ, et al., A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16: 3507-3516.
42. Schiller H, Akerley WL, Brugger W, et al., Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28:(abstr LBA 7502): 18s.
43. Weidner KM, Di Cesare S, Sachs M, et al., Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384: 173-176.
44. Day RM, Cioce V, Breckenridge D, et al., Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene 1999; 18: 3399-3406.
45. Potempa S, Ridley AJ,. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell 1998; 9: 2185-2200.
46. Xiao GH, Jeffers M, Bellacosa A, et al., Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001; 98: 247-252.
47. Brose MS, Volpe P, Feldman M, et al., BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
48. Riely GJ, Kris MG, Rosenbaum D, et al., Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14: 5731-5734.
49. Ahrendt SA, Decker PA, Alawi EA, et al., Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92: 1525-1530.
50. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
51. Jackman DM, Yeap BY, Lindeman NI, et al., Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 760-766.
52. Miller VA, Riely GJ, Zakowski MF, et al., Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26: 1472-1478.
53. Massarelli E, Varella-Garcia M, Tang X, et al., KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
54. Han SW, Kim TY, Jeon YK, et al., Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006; 12: 2538-2544.
55. Barbie DA, Tamayo P, Boehm JS, et al., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112.
56. Meylan E, Dooley AL, Feldser DM, et al., Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104-107.
57. Engelman JA, Chen L, Tan X, et al., Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356.
58. Forbes SA, Tang G, Bindal N, et al., COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010; 38: D652-657.
59. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
60. Chitale D, Gong Y, Taylor BS, et al., An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 2009; 28: 2773-2783.
61. Pratilas CA, Hanrahan AJ, Halilovic E, et al., Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68: 9375-9383.
62. Shepherd C, Puzanov I, Sosman JA,. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 2010; 12: 146-152.
63. Flaherty K, Puzanov I, Sosman J, et al., Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009; 27:(abstr 900): 15s.
64. Marks JL, Gong Y, Chitale D, et al., Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008; 68: 5524-5528.
65. Rinehart J, Adjei AA, Lorusso PM, et al., Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-4462.
66. Engelman JA, Luo J, Cantley LC,. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
67. Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
68. Baldus SE, Schaefer KL, Engers R, et al., Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
69. Kalinsky K, Jacks LM, Heguy A, et al., PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15: 5049-5059.
70. Ikenoue T, Kanai F, Hikiba Y, et al., Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005; 65: 4562-4567.
71. Shapiro G, Kwak E, Baselga J, et al., Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol 2009; 27:(abstr 3500): 15s.
72. Bleeker FE, Felicioni L, Buttitta F, et al., AKT1(E17K) in human solid tumours. Oncogene 2008; 27: 5648-5650.
73. Carpten JD, Faber AL, Horn C, et al., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007; 448: 439-444.
74. Tolcher AW, Yap TA, Fearen I, et al., A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J Clin Oncol 2009; 27:(abstr 3503): 15s.
75. Jin G, Kim MJ, Jeon HS, et al., PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010; 69: 279-283.
76. Sos ML, Koker M, Weir BA, et al., PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256-3261.
77. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al., An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-6091.
78. Mita MM, Tolcher AW,. The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep 2007; 9: 316-322.
79. Dancey J,. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7: 209-219.
80. Fumagalli D, Gavin PG, Taniyama Y, et al., A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 2010; 10: 101.
81. Dias-Santagata D, Akhavanfard S, David SS, et al., Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med; 2: 146-158.
82. Lurkin I, Stoehr R, Hurst CD, et al., Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010; 5: e8802. 83.
83. Su Z, Dias-Santagata D, Duke M, et al., A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small cell lung cancer. J Mol Diagn (in press).
84. Pan Q, Pao W, Ladanyi M,. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005; 7: 396-403.
85. Holmes A, Joshi VA, Kuang Y, et al., Comparison of genotyping with direct sequencing as a method to detect EGFR mutations in NSCLC. J Clin Oncol 2008; 26:(abstr 22013): 15s.
86. Penault-Llorca F, Bilous M, Dowsett M, et al., Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009; 132: 539-548.
87. Cataldo KA, Jalal SM, Law ME, et al., Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol 1999; 23: 1386-1392.
88. Knight ZA, Lin H, Shokat KM,. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-137.
89. Giamas G, Man YL, Hirner H, et al., Kinases as targets in the treatment of solid tumors. Cell Signal 2010; 22: 984-1002.
90. -/- colon carcinoma. Science 1997; 275: 1784-1787.
91. Ohgaki H, Kros JM, Okamoto Y, et al., APC mutations are infrequent but present in human lung cancer. Cancer Lett 2004; 207: 197-203.
92. Sunaga N, Kohno T, Kolligs FT, et al., Constitutive activation of the Wnt signaling pathway by CTNNB1 (β-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001; 30: 316-321.
93. Barker N, Clevers H,. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5: 997-1014.
94. Takahashi-Yanaga F, Kahn M,. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010; 16: 3153-3162.
95. You L, He B, Xu Z, et al., Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004; 23: 6170-6174.
96. Hurst JH, Hooks SB,. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol 2009; 78: 1289-1297.
97. Kan Z, Jaiswal BS, Stinson J, et al., Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
98. Gutkind JS,. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 1998; 17: 1331-1342.
99. Steelman LS, Abrams SL, Whelan J, et al., Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008; 22: 686-707.
100. Levine RL,. Janus kinase mutations. Semin Oncol 2009; 36: S6-11.
101. + myeloma cells. Am J Hematol 2010; 85: 675-686.
102. Lasho TL, Tefferi A, Hood JD, et al., TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation-negative patients. Leukemia 2008; 22: 1790-1792.
103. Ushijima T,. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223-231. (Pubitemid 40314953)
104. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
105. Wang H, Han H, Mousses S, et al., Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol 2006; 33: 513-520.
106. Metzker ML,. Sequencing technologies-the next generation. Nat Rev Genet 2010; 11: 31-46.
107. Hawkins RD, Hon GC, Ren B,. Next-generation genomics: an integrative approach. Nat Rev Genet 2010; 11: 476-486.